XBIO REPORT

Tag: $RNA

August 13, 2026

Atrium Therapeutics Announces Q2 2026 Financial Performance

NASDAQ: $RNA Overview of Q2 2026 Results Atrium Therapeutics has officially released its financial results for the second quarter of 2026. As the company continues to navigate the complex biopharmaceutical landscape, these latest figures offer stakeholders a detailed look at the organization’s fiscal health and operational progress during the three-month period ending June 30, 2026.…

Announcements

$RNA, Atrium Therapeutics, Biotechnology, Financial Results, Investor Relations, pr-newswire, Q2 2026
February 21, 2026

Landmark Results for Delpacibart Etedesiran in Myotonic Dystrophy Type 1 Published in The New England Journal of Medicine

NASDAQ: $RNA NEJM Publishes Phase 1/2 MARINA Trial Results for Delpacibart Etedesiran in DM1 Treatment Avidity Biosciences, Inc., a company pioneering a new class of RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCs™), has reached a significant milestone. The final results from the completed Phase 1/2 MARINA® trial investigating delpacibart etedesiran (del-desiran) for the treatment…

Clinical Trial

$RNA, AOC Therapeutics, Delpacibart Etedesiran, Myotonic Dystrophy Type 1, NEJM Publication, Phase 3 Trial
February 7, 2026

Avidity Biosciences Sets Record Date for Potential Spin-Off of RNA Therapeutics Business

NASDAQ: $RNA Avidity Biosciences, Inc. has recently announced a significant corporate development concerning its RNA therapeutics business. The company has established an expected record date for the potential separation of its RNA therapeutics business into an independent, publicly traded entity. The Potential Spin-Off Explained In a move designed to potentially maximize shareholder value and allow…

Announcements

$RNA, Avidity Biosciences, Biotechnology, Corporate Action, RNA Therapeutics, Spin-Off

Tag: $RNA

Atrium Therapeutics Announces Q2 2026 Financial Performance

Landmark Results for Delpacibart Etedesiran in Myotonic Dystrophy Type 1 Published in The New England Journal of Medicine

Avidity Biosciences Sets Record Date for Potential Spin-Off of RNA Therapeutics Business